Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 1:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Radiation Mucositis Clear all
Terminated Not applicable Interventional

MucoLox Formulation to Mitigate Mucositis Symptoms in Head/Neck Cancer

NCT03461354
View directory record Official record
Conditions
Mucositis Oral, Head and Neck Cancer
Interventions
MucoLox, Sodium Bicarbonate
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Jul 22, 2026, 1:59 PM EDT
Recruiting Phase 2 Interventional

Treatment of Radiation and Cisplatin Induced Toxicities with Tempol

NCT03480971
View directory record Official record
Conditions
Mucositis, Nephrotoxicity, Ototoxicity
Interventions
Tempol, Placebo Solution
Drug
Lead sponsor
Matrix Biomed, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
9
States / cities
La Jolla, California • Merced, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Jul 22, 2026, 1:59 PM EDT
Not listed No phase listed Observational

ZeroTolerance Mucositis: Managing Oral and Alimentary Mucositis With High Potency Sucralfate - ProThelial

NCT02016807
View directory record Official record
Conditions
Oral Mucositis, Nausea, Vomiting, Diarrhea
Interventions
ProThelial
Device
Lead sponsor
Ashley Downs Bioscience
Industry
Eligibility
18 Years to 95 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Foster, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Jul 22, 2026, 1:59 PM EDT
Completed Phase 3 Interventional Results available

Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy

NCT02229539
View directory record Official record
Conditions
Acute Oral Mucositis Pain
Interventions
doxepin hydrochloride oral solution, DLA (diphenhydramine, lidocaine and antacids) rinse, Placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
350
States / cities
Anchorage, Alaska • Burbank, California • Dublin, California + 221 more
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Jul 22, 2026, 1:59 PM EDT
Completed Phase 3 Interventional Results available

GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer

NCT00293462
View directory record Official record
Conditions
Head and Neck Cancer, Mucositis Oral, Radiation Toxicity, Tongue Cancer
Interventions
sargramostim, oral salt and soda mouthwash
Biological · Other
Lead sponsor
Marilyn Dodd
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Jul 22, 2026, 1:59 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

NCT01403064
View directory record Official record
Conditions
Oral Mucositis
Interventions
ALD518, 0.9% saline
Biological · Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Clearwater, Florida • Boston, Massachusetts • Detroit, Michigan + 10 more
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Jul 22, 2026, 1:59 PM EDT
Terminated Phase 3 Interventional Results available

Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer

NCT00360971
View directory record Official record
Conditions
Head and Neck Cancer, Mucositis, Pain, Radiation Toxicity
Interventions
palifermin, cisplatin, placebo, neck dissection, radiation therapy
Biological · Drug · Other + 2 more
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
47
States / cities
Scottsdale, Arizona • Auburn, California • Burbank, California + 40 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2017 · Synced Jul 22, 2026, 1:59 PM EDT
Terminated Phase 1 Interventional

Safety of Phenylephrine for Oral Mucositis Prevention

NCT01092975
View directory record Official record
Conditions
Mucositis, Stomatitis
Interventions
phenylephrine solution
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 27, 2020 · Synced Jul 22, 2026, 1:59 PM EDT
Completed No phase listed Observational

Evaluation of the Role of Prostaglandins in Radiation-induced Mucositis

NCT01252498
View directory record Official record
Conditions
Cancer of the Head and Neck, Radiotherapy
Interventions
Not listed
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Jul 22, 2026, 1:59 PM EDT
Completed Phase 1 Interventional

Edible Plant Exosome Ability to Prevent Oral Mucositis Associated With Chemoradiation Treatment of Head and Neck Cancer

NCT01668849
View directory record Official record
Conditions
Head and Neck Cancer, Oral Mucositis
Interventions
Grape extract, Lortab, Fentanyl patch, mouthwash
Dietary Supplement · Drug
Lead sponsor
University of Louisville
Other
Eligibility
20 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Jul 22, 2026, 1:59 PM EDT
Completed Not applicable Interventional

Photobiomodulation to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Head & Neck Cancer Patients

NCT03972527
View directory record Official record
Conditions
Oral Mucositis (Ulcerative), Oral Mucositis (Ulcerative) Due to Radiation, Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy, Head and Neck Cancer
Interventions
Photobiomodulation, Routine Oral Care and Analgesia
Device · Other
Lead sponsor
MuReva Phototherapy Inc.
Industry
Eligibility
22 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • Long Beach, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Jul 22, 2026, 1:59 PM EDT
Completed Not applicable Interventional Results available

Study of Personalized Sterile Humidification Device for Mucositis in Head and Neck Cancer Patients

NCT01930435
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Sterile Humidification Device
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Jul 22, 2026, 1:59 PM EDT
Terminated Phase 1Phase 2 Interventional

The Effects of Whole Food Intervention on Mucositis in Patients Treated for Head and Neck Cancer

NCT02575313
View directory record Official record
Conditions
Mucositis
Interventions
Whole Food Intervention
Dietary Supplement
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 13, 2015 · Synced Jul 22, 2026, 1:59 PM EDT
Completed Phase 3 Interventional Results available

ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients

NCT03689712
View directory record Official record
Conditions
Oral Mucositis
Interventions
GC4419 90mg, Placebo
Drug
Lead sponsor
Galera Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
86
States / cities
Gilbert, Arizona • Jonesboro, Arkansas • Corona, California + 77 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Jul 22, 2026, 1:59 PM EDT
Completed Phase 1 Interventional

A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck

NCT01921426
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Oropharynx
Interventions
GC4419
Drug
Lead sponsor
Galera Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
10
States / cities
Lakeland, Florida • Iowa City, Iowa • St Louis, Missouri + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2016 · Synced Jul 22, 2026, 1:59 PM EDT
Not listed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07 in Attenuating Oral Mucositis in Subjects With Head and Neck Cancer

NCT01247246
View directory record Official record
Conditions
Oral Mucositis
Interventions
SCV-07, Placebo
Drug
Lead sponsor
SciClone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
49
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated May 25, 2014 · Synced Jul 22, 2026, 1:59 PM EDT
Completed Not applicable Interventional Results available

Low-Level Laser Therapy for Prevention of Oral Mucositis

NCT02723604
View directory record Official record
Conditions
Mucositis
Interventions
Low Level Laser Therapy
Device
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 26, 2023 · Synced Jul 22, 2026, 1:59 PM EDT
Not yet recruiting Phase 2 Interventional

Head and Neck Cancer Patients With Oral Mucositis Treated With Ketamine Oral Rinse

NCT06660017
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Placebo, Ketamine Topical
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 22, 2026, 1:59 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Efficacy of Ketamine Mouthwash in the Management of Oral and Pharyngeal Toxicity Associated With Head and Neck Chemoradiotherapy: A Phase 2, Simon 2-stage Trial

NCT05331131
View directory record Official record
Conditions
Cancer of Head and Neck, Mucositis Oral, Pharyngeal Mucositis
Interventions
Ketamine Topical
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Jul 22, 2026, 1:59 PM EDT
Terminated Phase 2 Interventional Results available

Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy

NCT01682031
View directory record Official record
Conditions
Chemotherapeutic Agent Toxicity, Mucositis, Radiation Toxicity, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Xerostomia
Interventions
selenomethionine, placebo, cisplatin, radiation therapy, quality-of-life assessment
Dietary Supplement · Other · Drug + 2 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Jul 22, 2026, 1:59 PM EDT
Active, not recruiting Phase 2 Interventional

RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer

NCT05966194
View directory record Official record
Conditions
Oral Mucositis
Interventions
RRx-001, Intensity Modulated Radiation Therapy (IMRT), Cisplatin for injection 100 mg/m2
Drug · Radiation
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
14
States / cities
Gilbert, Arizona • Tucson, Arizona • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 22, 2026, 1:59 PM EDT
Completed Phase 2Phase 3 Interventional

Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer

NCT00002533
View directory record Official record
Conditions
Head and Neck Cancer, Infection, Oral Complications
Interventions
fluconazole, radiation therapy
Drug · Radiation
Lead sponsor
University of Miami
Other
Eligibility
21 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Jul 22, 2026, 1:59 PM EDT
Terminated Phase 2 Interventional Results available

Combination Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer

NCT00352118
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
filgrastim, pegfilgrastim, cisplatin, docetaxel, fluorouracil, conventional surgery, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Jul 22, 2026, 1:59 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer

NCT02508389
View directory record Official record
Conditions
Radiation Induced Oral Mucositis
Interventions
Low Dose GC4419: 30mg/day, High Dose GC4419: 90mg/day, Placebo, Intensity-Modulated Radiation Therapy, Cisplatin
Drug · Radiation
Lead sponsor
Galera Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
60
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2021 · Synced Jul 22, 2026, 1:59 PM EDT